Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular and hyaluronic acid injections; peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis; and Stimrouter to treat chronic peripheral pain, and TalisMann provides stimulation to the targeted peripheral nerve, as well as XCELL PRP System, a benchtop device that processes whole blood to produce high-yield PRP with a 10-minute single-spin cycle. It also offers precision bone resection for patients with degenerative spine conditions and spinal deformities, as well as enables precision ultrasonic neuro and general surgery to address brain tumors and pathologies of the liver and other organs; and bone graft substitutes, including various products that facilitate optimal bone fusion. In addition, the company provides neXus, an ultrasonic surgical system; BoneScalpel, a surgical solution enabling precise cuts in hard tissue; BoneScalpel Access, for bone removal with visualization; SonaStar system, a precise ablation and removal of soft tissue; SonaStar Elite handpiece and accessories; SonicOne, an ultrasonic cleansing and debridement system; Osteoamp, an allograft-derived bone graft for orthopedic, neurosurgical, and reconstructive bone grafting procedures; Signafuse bone graft; Purebone, a natural osteoconductive scaffold; and Reficio demineralized bone matrix. The company's restorative therapies include minimally invasive fracture treatments and rehabilitation products. Its products also include Exogen, an ultrasound bone stimulation system. The company sells its products to healthcare institutions, physicians, patients, distributors and dealers. Bioventus Inc. was founded in 2011 and is headquartered in Durham, North Carolina.…
Bioventus (BVS) Stock Price Slides After Q3 Results Cut Revenue Outlook
Bioventus (NASDAQ: BVS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 960 employees.
The shares were at 9.880 USD on 20 November 2026, up 32.6% over 52 weeks. Its 52-week range is 6.470 USD to 15.89 USD: the price is 37.8% below the high and 52.7% above the low.
At a market capitalisation of 676.53M USD, it trades at 12.2 times trailing earnings and 11.1 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a discount of 52% for BVS.
Bioventus reports return on equity of 12.3%, an operating margin of 10.1% and revenue up 2.7% year over year.
Its debt exceeds its cash by 211.12M USD, a debt-to-equity ratio of 1.60. Its Piotroski F-score is 8 out of 9, a strong reading of its financial health. 5 analysts cover the stock; their mean price target of 16.60 USD is 68.0% above the current price. The next earnings report is expected on 9 March 2027.